Comparative Pharmacology
Head-to-head clinical analysis: DURADYNE DHC versus EXALGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURADYNE DHC versus EXALGO.
DURADYNE DHC vs EXALGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
Mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Initial: 8 mg orally every 24 hours for opioid-naive patients; titration based on response; maximum 32 mg daily.
None Documented
None Documented
Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours.
Terminal elimination half-life: approximately 15-18 hours in healthy adults. Steady state is achieved by 3-5 days. In patients with hepatic impairment, half-life may be prolonged up to 24-27 hours.
Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile.
Renal: primarily as hydromorphone-3-glucuronide and unchanged drug (~40% as glucuronide conjugates, ~3% as unchanged hydromorphone). Fecal: minimal. Total renal clearance accounts for ~50% of drug elimination.
Category C
Category C
Opioid Analgesic
Opioid Analgesic